BC Extra | Mar 1, 2019
Company News

Ex-Merck China R&D head joins Ascletis as CMO

Antiviral and cancer company Ascletis Pharma Inc. (HKSE:1672) hired Zhengqing Li as CMO and president of R&D Greater China. He was global VP of MSD China and general manager of the Merck & Co. Inc....
BioCentury | Apr 7, 2017
Finance

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
BC Innovations | Jan 11, 2017
Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Mouse studies suggest inhibiting IFNAR2 or IFNAR1 could help treat HIV1 infection. In a humanized mouse model of chronic HIV infection, an anti-IFNAR2 mAb decreased plasma viral load and levels of exhaustion markers...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Week In Review | Aug 8, 2016
Clinical News

Isentress raltegravir: Additional Phase III data

Additional data from the 96-week, double-blind, international Phase III ONCEMRK trial in 797 treatment-naive patients with HIV-1 infection showed that a once-daily formulation of 1,200 mg Isentress (dosed as two 600 mg tablets) plus Truvada...
BC Week In Review | Feb 29, 2016
Clinical News

Isentress raltegravir: Phase III data

Top-line data from the 96-week, double-blind, international Phase III ONCEMRK trial in about 750 treatment-naive patients with HIV-1 infection trial showed that a once-daily formulation of 1,200 mg raltegravir (dosed as two 600 mg tablets)...
BC Innovations | Aug 6, 2015
Targets & Mechanisms

Rethinking the reservoir

It's time to rethink using "shock and kill" in HIV - a strategy that has made no serious progress in the last 16 years towards its goal of getting patients permanently off antiretroviral therapy (ART) - according...
BC Week In Review | Mar 23, 2015
Clinical News

BMS-663068: Additional Phase IIb data

Additional data from the double-blind Phase IIb AI438011 trial in 251 evaluable treatment-experienced patients with HIV-1 infection showed that 61-82% of patients receiving BMS-663068 as an add-on to Isentress raltegravir plus Viread tenofovir achieved a...
BC Week In Review | Mar 2, 2015
Company News

Merck & Co. Inc, Medicines Patent Pool deal

Merck granted the Medicines Patent Pools a non-exclusive license to pediatric formulations of raltegravir to treat HIV infection in children at least four weeks old. The license allows generic manufacturers and companies to develop, manufacture...
BC Week In Review | Jan 26, 2015
Clinical News

Dutrebis lamivudine/raltegravir regulatory update

EMA’s CHMP recommended approval of Dutrebis lamivudine/raltegravir to treat HIV-1 infection in patients ages ³6 and weighing ³30 kg. According to CHMP, Dutrebis reduces the daily pill burden while retaining comparable efficacy to the individual...
Items per page:
1 - 10 of 135